Function and Regulation of Dyrk1A: Towards Understanding Down Syndrome

Overview

Journal Cell Mol Life Sci

Publisher Springer

Specialty Biology

Date 2009 Aug 18

PMID 19685005

Citations 103

Authors

Joongkyu Park

Woo-Joo Song

Kwang Chul Chung

Affiliations

Soon will be listed here.

Abstract

Down syndrome (DS) is associated with a variety of symptoms, such as incapacitating mental retardation and neurodegeneration (i.e., Alzheimer's disease), that prevent patients from leading fully independent lives. These phenotypes are a direct consequence of the overexpression of chromosome 21 genes, which are present in duplicate due to non-disjunction of chromosome 21. Accumulating data suggest that the chromosome 21 gene product, dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (Dyrk1A), participates in the pathogenic mechanisms underlying the mental and other physical symptoms of DS. In this review, we summarize the evidence supporting a role for Dyrk1A in DS, especially DS pathogenesis. Recently, several natural and synthetic compounds have been identified as Dyrk1A inhibitors. Understanding the function and regulation of Dyrk1A may lead to the development of novel therapeutic agents aimed at treating DS.

Citing Articles

Protein Kinases in Obesity, and the Kinase-Targeted Therapy.

Engin A Adv Exp Med Biol. 2024; 1460:199-229.

PMID: 39287853 DOI: 10.1007/978-3-031-63657-8_7.

Association of genetic variants with autism spectrum disorder in Japanese children revealed by targeted sequencing.

Shiota Y, Nishiyama T, Yokoyama S, Yoshimura Y, Hasegawa C, Tanaka S Front Genet. 2024; 15:1352480.

PMID: 39280100 PMC: 11395840. DOI: 10.3389/fgene.2024.1352480.

Sex-specific trisomic Dyrk1a-related skeletal phenotypes during development in a Down syndrome model.

LaCombe J, Sloan K, Thomas J, Blackwell M, Crawford I, Bishop F Dis Model Mech. 2024; 17(9).

PMID: 39136051 PMC: 11449447. DOI: 10.1242/dmm.050914.

Nuclear F-actin assembly on damaged chromatin is regulated by DYRK1A and Spir1 phosphorylation.

Li J, Xiong N, West K, Leung M, Ching Y, Huang J Nucleic Acids Res. 2024; 52(15):8897-8912.

PMID: 38966995 PMC: 11347173. DOI: 10.1093/nar/gkae574.

Human Cytomegalovirus Dysregulates Cellular Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases and Sonic Hedgehog Pathway Proteins in Neural Astrocyte and Placental Models.

Egilmezer E, Hamilton S, Lauw G, Follett J, Sonntag E, Schutz M Viruses. 2024; 16(6).

PMID: 38932210 PMC: 11209403. DOI: 10.3390/v16060918.

References

Kim E, Sung J, Lee H, Rhim H, Hasegawa M, Iwatsubo T . Dyrk1A phosphorylates alpha-synuclein and enhances intracellular inclusion formation. J Biol Chem. 2006; 281(44):33250-7. DOI: 10.1074/jbc.M606147200. View

Siarey R, Stoll J, Rapoport S, Galdzicki Z . Altered long-term potentiation in the young and old Ts65Dn mouse, a model for Down Syndrome. Neuropharmacology. 1998; 36(11-12):1549-54. DOI: 10.1016/s0028-3908(97)00157-3. View

Fotaki V, Dierssen M, Alcantara S, Martinez S, Marti E, Casas C . Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice. Mol Cell Biol. 2002; 22(18):6636-47. PMC: 135639. DOI: 10.1128/MCB.22.18.6636-6647.2002. View

Benavides-Piccione R, Dierssen M, Ballesteros-Yanez I, Martinez de Lagran M, Arbones M, Fotaki V . Alterations in the phenotype of neocortical pyramidal cells in the Dyrk1A+/- mouse. Neurobiol Dis. 2005; 20(1):115-22. DOI: 10.1016/j.nbd.2005.02.004. View

Wegiel J, Dowjat K, Kaczmarski W, Kuchna I, Nowicki K, Frackowiak J . The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome. Acta Neuropathol. 2008; 116(4):391-407. PMC: 2656568. DOI: 10.1007/s00401-008-0419-6. View

Skurat A, Dietrich A . Phosphorylation of Ser640 in muscle glycogen synthase by DYRK family protein kinases. J Biol Chem. 2003; 279(4):2490-8. DOI: 10.1074/jbc.M301769200. View

Ryoo S, Jeong H, Radnaabazar C, Yoo J, Cho H, Lee H . DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease. J Biol Chem. 2007; 282(48):34850-7. DOI: 10.1074/jbc.M707358200. View

Reeves R, Irving N, Moran T, WOHN A, Kitt C, Sisodia S . A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet. 1995; 11(2):177-84. DOI: 10.1038/ng1095-177. View

Galceran J, de Graaf K, Tejedor F, Becker W . The MNB/DYRK1A protein kinase: genetic and biochemical properties. J Neural Transm Suppl. 2004; (67):139-48. DOI: 10.1007/978-3-7091-6721-2_12. View

10.

Ryoo S, Cho H, Lee H, Jeong H, Radnaabazar C, Kim Y . Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease. J Neurochem. 2007; 104(5):1333-44. DOI: 10.1111/j.1471-4159.2007.05075.x. View

11.

Wisniewski K, Wisniewski H, Wen G . Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol. 1985; 17(3):278-82. DOI: 10.1002/ana.410170310. View

12.

Altafaj X, Dierssen M, Baamonde C, Marti E, Visa J, Guimera J . Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. Hum Mol Genet. 2001; 10(18):1915-23. DOI: 10.1093/hmg/10.18.1915. View

13.

Rahmani Z, Blouin J, Watkins P, Mattei J, POISSONNIER M, PRIEUR M . Critical role of the D21S55 region on chromosome 21 in the pathogenesis of Down syndrome. Proc Natl Acad Sci U S A. 1989; 86(15):5958-62. PMC: 297750. DOI: 10.1073/pnas.86.15.5958. View

14.

Maenz B, Hekerman P, Vela E, Galceran J, Becker W . Characterization of the human DYRK1A promoter and its regulation by the transcription factor E2F1. BMC Mol Biol. 2008; 9:30. PMC: 2292204. DOI: 10.1186/1471-2199-9-30. View

15.

Burger P, Vogel F . The development of the pathologic changes of Alzheimer's disease and senile dementia in patients with Down's syndrome. Am J Pathol. 1973; 73(2):457-76. PMC: 1904076. View

16.

Kim D, Won J, Shin D, Kang J, Kim Y, Choi S . Regulation of Dyrk1A kinase activity by 14-3-3. Biochem Biophys Res Commun. 2004; 323(2):499-504. DOI: 10.1016/j.bbrc.2004.08.102. View

17.

Koo K, Kim N, Chon Y, Jung M, Lee B, Kim J . QSAR analysis of pyrazolidine-3,5-diones derivatives as Dyrk1A inhibitors. Bioorg Med Chem Lett. 2009; 19(8):2324-8. DOI: 10.1016/j.bmcl.2009.02.062. View

18.

Hammerle B, Elizalde C, Galceran J, Becker W, Tejedor F . The MNB/DYRK1A protein kinase: neurobiological functions and Down syndrome implications. J Neural Transm Suppl. 2004; (67):129-37. DOI: 10.1007/978-3-7091-6721-2_11. View

19.

Baek K, Zaslavsky A, Lynch R, Britt C, Okada Y, Siarey R . Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature. 2009; 459(7250):1126-30. PMC: 2724004. DOI: 10.1038/nature08062. View

20.

Olson L, Roper R, Sengstaken C, Peterson E, Aquino V, Galdzicki Z . Trisomy for the Down syndrome 'critical region' is necessary but not sufficient for brain phenotypes of trisomic mice. Hum Mol Genet. 2007; 16(7):774-82. DOI: 10.1093/hmg/ddm022. View